Diana Bilton is Honorary Clinical Senior Lecturer and Director of the Adult Cystic Fibrosis Service at Royal Brompton Hospital.
Diana trained in Manchester graduating in 1984.After completing general training she became a UK Cystic Fibrosis Trust research fellow with Professor Kevin Webb examining the influence of antioxidant status on pulmonary and pancreatic disease . This early research inspired Diana's career long interest in evaluating new diagnostic and therapeutic approaches to the continued vicious cycle of infection and inflammation in Cystic Fibrosis and Non CF Bronchiectasis.
Diana has been global chief investigator on trials of new therapies for Cystic Fibrosis and nonCF Bronchiectasis. Recent studies have included randomised trials of Inhaled Dry Powder Mannitol as well as investigation of novel inhaled antibiotic preparations.
Diana is joint PI with Dr Jane Davies of the European CF Society Clinical Trials Network site at Royal Brompton .
et al., 2016, Corrigendum to "Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study" [J Cyst Fibros (2015) 632-638]., J Cyst Fibros
et al., 2016, HbA1c as a screening tool for cystic fibrosis related diabetes, Journal of Cystic Fibrosis, Vol:15, ISSN:1569-1993, Pages:251-257
et al., 2016, HbA1c as a screening tool for cystic fibrosis related diabetes Response, Journal of Cystic Fibrosis, Vol:15, ISSN:1569-1993, Pages:265-266
et al., 2016, Antipseudomonal Bacteriophage Reduces Infective Burden and Inflammatory Response in Murine Lung, Antimicrobial Agents and Chemotherapy, Vol:60, ISSN:0066-4804, Pages:744-751
et al., 2016, Variability of sweat chloride concentration in subjects with cystic fibrosis and G551D mutations., J Cyst Fibros